8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape: October 2026 Update

Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on a NeurologyLive feature (September 13, 2026) and the latest news reports listed below. 



Muscular dystrophy treatment is changing fast. For many years, care meant supporting the muscles, heart and lungs. Today, scientists are testing medicines that act on the root cause of different types: faulty genetic messages in Duchenne and myotonic dystrophy, and a gene that switches on by mistake in FSHD. To mark Muscular Dystrophy Awareness Month in September, NeurologyLive published a list of eight emerging therapies to watch. This article summarises them in simple words, adds the newest news from October 2026, and explains what it all means for families in Pakistan. None of these therapies is available in Pakistan at present.

Quick facts

  • The eight therapies cover Duchenne (DMD), myotonic dystrophy type 1 (DM1) and FSHD.
  • Most are still being tested in clinical trials. A few are under FDA review.
  • A Duchenne cell therapy (deramiocel) has an FDA decision date of November 22, 2026.
  • A Novartis phase 3 trial in DM1 did not meet its main goal in September 2026, a reminder that progress is not guaranteed.
  • A genetic diagnosis, including the exact gene change or repeat size, is increasingly the key to joining trials.

The 8 Therapies at a Glance

TherapyConditionLatest status (2026)
1. Z-rostudirsen (DYNE-251)Duchenne, exon 51BLA submitted to the FDA on May 26, 2026, seeking accelerated approval
2. DeramiocelDuchenneFDA decision date extended to November 22, 2026
3. Del-desiranDM1Phase 3 HARBOR did not meet its main goal (September 8, 2026)
4. Z-basivarsenDM1Positive early data; phase 3 planned for 2026
5. Del-braxFSHDFDA open to accelerated approval pathway; confirmatory phase 3 started
6. DYNE-302FSHDFDA cleared a phase 1 trial in July 2026
7. SRP-1001 (ARO-DUX4)FSHD1Phase 1/2; early data in March 2026
8. PGN-EDODM1DM1Phase 2; moving to the highest dose in August 2026


Duchenne Muscular Dystrophy

1. Z-rostudirsen (formerly DYNE-251): exon 51 skipping

This is a new type of exon-skipping medicine for boys whose gene change is amenable to skipping exon 51, the same target as eteplirsen. It is joined to a fragment of an antibody that carries it into muscle cells. Dyne Therapeutics has submitted an application to the FDA asking for accelerated approval, which would be a major regulatory step if accepted. Like all exon-skipping medicines, it only suits boys with a matching genetic change, so a detailed genetic report matters.

2. Deramiocel: cell therapy

Deramiocel is a donor heart-derived cell therapy that is not tied to one gene change, and the trial included older, mostly non-walking patients. The FDA extended its review to November 22, 2026, after an advisory panel voted against recommending approval. Read our detailed update on deramiocel and the HOPE-3 trial on this blog.

Myotonic Dystrophy Type 1 (DM1)

DM1 is caused by a repeat expansion that makes a toxic genetic message. Several medicines aim to remove or block it. You can read about DM1 in our guide: Myotonic Dystrophy (DM1 and DM2): Symptoms, Causes and Treatment.

3. Del-desiran (Novartis): a setback

The phase 3 HARBOR study tested del-desiran in DM1. On September 8, 2026, Novartis announced that it did not meet its main goal, which was a video-based measure of how quickly the hand opens after gripping (a measure of myotonia). The company said it saw signs of clinical activity in secondary and exploratory results, and that the full data are being evaluated. This is a reminder that even well-designed late-stage trials can fail, and that science moves step by step.

4. Z-basivarsen (Dyne): encouraging early data

In the early ACHIEVE trial, Dyne reported consistent improvements in myotonia, muscle strength and brain-related measures, with gains sustained through 12 months. The company is planning a phase 3 trial in 2026, and calls the medicine a potential first-in-class DM1 therapy. These are early data in small groups.

5. PGN-EDODM1 (PepGen): a peptide-linked medicine

This medicine is built to enter muscle, bind the toxic DM1 genetic message and release a protein that is trapped by it, helping the cell to read genes correctly again. In the phase 2 FREEDOM2 study, the lowest dose looked safe and showed trends towards better gene reading and hand opening. In August 2026, after a safety board review, PepGen said it would move to the highest planned dose.

Facioscapulohumeral Muscular Dystrophy (FSHD)

FSHD is caused by the DUX4 gene switching on by mistake in muscle. Treatments that reduce DUX4 are now in human trials. Learn more in our guide: Facioscapulohumeral Muscular Dystrophy (FSHD): Face, Shoulder and Arm Weakness.

6. Del-brax (Avidity)

Del-brax is an antibody-linked RNA medicine aimed at DUX4. The company has said that the FDA is open to an accelerated approval pathway, and it has started a large phase 3 trial (FORWARD) to confirm the benefit.

7. DYNE-302

Dyne's FSHD medicine combines an antibody fragment that targets muscle with a small RNA that reduces DUX4. In July 2026, the FDA cleared the start of a phase 1 trial in walking adults with FSHD, the first step into human testing.

8. SRP-1001 (formerly ARO-DUX4)

Sarepta is developing this small interfering RNA medicine, delivered to muscle through a muscle-targeting approach. In first human data in March 2026, it reached muscle, lowered a muscle damage marker (creatine kinase) and looked acceptably safe. Studies at higher doses are planned.

More Duchenne News from the Past Week

  • RGX-202 (gene therapy): On October 16, 2026, results of the pivotal AFFINITY DUCHENNE phase 3 trial were reported. The study met its main goal, with microdystrophin levels above the pre-set threshold in 93% of participants who could be evaluated, and early functional findings favouring treatment over external controls.
  • INS1201 (gene therapy): A phase 1 trial called ASCEND is testing a single dose, given into the spinal fluid (intrathecal), of an AAV9 gene therapy in young boys with Duchenne.
  • ELEVIDYS: New data from the World Muscle Society Congress in boys aged 8 to 12 were presented, and we explain them in a separate article on this blog.

What This Means for Families in Pakistan

  • None of these is available in Pakistan. Most are in trials or under review, and trials are run in other countries.
  • Genetic diagnosis is the key. Exon-skipping medicines need a matching deletion, DM1 trials need a confirmed repeat expansion, and FSHD trials need a confirmed FSHD test. Please get the exact genetic report.
  • Registration matters. Patients who are counted and diagnosed are the ones who can be reached when trials or access programmes open.
  • Be careful with offers. Anyone selling an "experimental" injection or a "stem cell" treatment for muscular dystrophy outside a registered trial is a danger to patients.
  • Basic care still comes first: heart and breathing checks, vaccines, steroids where advised and early diagnosis۔
Muscular Dystrophy Pakistan
Every patient counts. Register with MDP.
Patients and families living with muscular dystrophy and other neuromuscular disorders can register on the MDP patient registration portal. Your registration helps us understand the real picture and speak up for timely diagnosis, care and support.
✔ Simple online registration
✔ For patients and families
✔ Helps make every patient visible
Register Now →
musculardystrophypk.org/registration

Frequently Asked Questions

Are these therapies approved?

No. They are investigational, and a few are under FDA review. None is approved yet for these indications as far as we know.

Can patients in Pakistan join these trials?

Trials usually enrol patients in the countries where they are run. A confirmed genetic diagnosis and registration with a patient registry are the best preparation.

Does a failed trial like del-desiran mean the end of that approach?

Not necessarily. The company saw signs of activity in other measures and is analysing the full data. Other DM1 medicines are still in testing.

Which one will reach patients first?

That is not known. Regulators have set a decision date of November 22, 2026 for deramiocel, and other applications are under review or planned.

Hope Built Step by Step

Every therapy on this list started as a lab idea, and every one has to pass strict tests. Some will succeed and some will not, but the number of programmes in Duchenne, DM1 and FSHD has never been higher. Follow the MDP blog for the next update, and make sure that the patients of Pakistan are counted.

Sources and Further Reading

Medical disclaimer: This article is for awareness and education only. It is not a substitute for professional medical advice, diagnosis or treatment. Investigational therapies are not approved and their safety and benefit are not proven. Please consult a qualified doctor about any medical concern.




Comments

Post a Comment

Popular posts from this blog

Deramiocel for Duchenne: HOPE-3 Results and the FDA Decision Due November 22, 2026

Image
Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on reports from NeurologyLive, Parent Project Muscular Dystrophy and Capricor Therapeutics (see sources below). Deramiocel , developed by Capricor Therapeutics, is an experimental cell therapy for Duchenne muscular dystrophy that has had a very bumpy road with the US regulator. It was rejected once in 2025, resubmitted after a phase 3 trial called HOPE-3, reviewed by an expert panel that voted against it in July 2026, and is now waiting for a final FDA decision on November 22, 2026 . At the 2026 World Muscle Society Congress, the company also shared new 24-month data. This article explains, in simple words, what deramiocel is, what the trial found, why the experts were divided, and what it means for families in Pakistan. For Duchenne basics, read our guide: Duchenne Muscular Dystrophy (DMD): Symptoms, Causes, Life Expectancy and Treatment . Quick facts Deramiocel is made of donor heart-derived cells (allogenei...
Read more

Stay Healthy This Respiratory Season: Flu, RSV and COVID-19 Tips for Muscular Dystrophy Families

Image
Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on guidance from Parent Project Muscular Dystrophy (published October 5, 2026), the US CDC and published care guidelines (see sources below). Published: October 17, 2026. As schools are in session and winter approaches, respiratory viruses such as influenza (flu), RSV and COVID-19 spread more easily. For most people, these infections are a few days of illness. For people with muscular dystrophy, whose breathing and coughing muscles may be weak, they can be much more dangerous, because weak muscles make it harder to clear mucus and fight infection. Parent Project Muscular Dystrophy has just published guidance for Duchenne and Becker families on how to prepare, and the same principles are widely useful for people with other muscular dystrophies whose breathing muscles are affected. This article puts that advice in simple words and adapts it for families in Pakistan. For more on these two conditions, read our guides ...
Read more

ELEVIDYS for Duchenne: New Data from the 2026 World Muscle Society Congress

Image
Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on reports from Parent Project Muscular Dystrophy, NeurologyLive and Sarepta Therapeutics (see sources below). Published: October 17, 2026. The 31st Congress of the World Muscle Society, held in Hiroshima, Japan, brought new numbers on ELEVIDYS (delandistrogene moxeparvovec), the gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics. The data were presented on September 30, 2026. This article explains what the new results show, what they do not show, what the safety label says, what the treatment costs, and what it means for families in Pakistan. For background on Duchenne itself, read our complete guide: Duchenne Muscular Dystrophy (DMD): Symptoms, Causes, Life Expectancy and Treatment . Quick facts ELEVIDYS is a one-time intravenous gene therapy that delivers a shortened, working copy of the dystrophin gene (micro-dystrophin) to muscle cells. New data compared 25 walking boys aged 8 to ...
Read more